Trastuzumab emtansine: A review of its use in patients with her2-positive advanced breast cancer previously treated with trastuzumab-based therapy

Drugs

Volumn 74, Issue 6, 2014, Pages 675-686

  Dhillon, Sohita ^a  

^a NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; MAYTANSINE; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL PRACTICE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERBILIRUBINEMIA; MULTICENTER STUDY (TOPIC); NONHUMAN; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; METABOLISM; METASTASIS; PATHOLOGY; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MAYTANSINE; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; SURVIVAL RATE;

EID: 84899937764     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0201-0     Document Type: Article

References (56)

1. World Health Organization. Breast cancer: prevention and control. 2014. http://www.who.int/cancer/detection/breastcancer/en/index1.html. Accessed 4 Mar 2014.
2. Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14(4):320-68.
3. Hurvitz SA, Kakkar R. The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies. Ther Adv Med Oncol. 2012;4(5):235-45.
4. Burris HA III, Tibbitts J, Holden SN, et al. Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. Clin Breast Cancer. 2011;11(5):275-82.
5. Genentech Inc. Kadcyla™ (ado-trastuzumab emtansine): US prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/ 125427s012lbl.pdf. Accessed 4 Mar 2014.
6. European Medicines Agency. Kadcyla (trastuzumab emtansine): summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/002389/WC500158593.pdf. Accessed 4 Mar 2014.
7. Genentech. FDA approves Genentech's Kadcyla (ado-trastuzumab emtansine), the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer [media release]. 22 Feb 2013. http://www.gene.com/media/press-releases/ 14347/2013-02-22/fda-approves-genentechs-kadcyla-ado-tras.
8. Diéras V, Bachelot T. The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. Target Oncol. 2013. doi: 10.1007/s11523-013-0287-4.
9. Austin CD, De Maziere AM, Pisacane PI, et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell. 2004;15(12):5268-82.
10. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006;66(8):4426-33.
11. Oroudjev E, Lopus M, Wilson L, et al. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther. 2010;9(10):2700-13.
12. Barok M, Tanner M, Koninki K, et al. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res. 2011;13(2):R46.
13. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280-90.
14. Junttila TT, Li G, Parsons K, et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011;128(2):347-56.
15. Li G, Fields CT, Parsons KL, et al. Trastuzumab-DM1: mechanisms of action and mechanisms of resistance [abstract no. 223]. EJC Suppl. 2010;8(7):73.
16. Honig A, Diessner J, Dietl J, et al. T-DM1 and pertuzumab as new tools for HER2 specific antibody-therapy against breast cancer stem cells in HER2-positive mammary carcinoma [abstract no. P1-04-05 plus poster]. Cancer Res. 2011;71(24 Suppl 3).
17. Lewis Phillips G, Fields C, Crocker L, et al. Potent anti-tumor activity of trastuzumab-DM1 antibody-drug conjugate in combination with cytotoxic chemotherapeutic agents, antibodies or small molecule kinase inhibitors [abstract no. 2133]. In: 99th Annual Meeting of the American Association for Cancer Research; 12-16 Apr 2008; San Diego (CA).
18. Lewis Phillips GD, Fields CT, Li G, et al. Dual targeting of HER2-positive cancer with trastuzumab-emtansine (T-DM1) and pertuzumab: critical role for neuregulin blockade in anti-tumor response to combination therapy. Clin Cancer Res. 2013;20(2):456-68.
19. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28(16):2698-704.
20. Aogi K, Ando M, Iwata H, et al. Phase I study of single agent trastuzumab emtansine in Japanese patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (JO22591) [abstract no. P1-12-19 plus poster]. Cancer Res. 2011;71(24 Suppl 3).
21. Burris HA III, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398-405.
22. Masuda N, Ito Y, Takao S, et al. A multicenter phase 2 study (JO22997) evaluating the efficacy and safety of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive metastatic breast cancer. Cancer Res. 2012;72(24 Suppl 3):472s.
23. Krop IE, LoRusso P, Miller KD, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012;30(26):3234-41.
24. Hurvitz SA, Dirix L, Kocsis J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer [erratum appears in J Clin Oncology. 2013; 31(23): 2977]. J Clin Oncol. 2013;31(9):1157-63.
25. Gupta M, Wang B, Carrothers TJ, et al. Effects of trastuzumab emtansine (T-DM1) on QT interval and safety of pertuzumab plus T-DM1 in patients with previously treated human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Pharm Drug Dev. 2013;2(1):11-24.
26. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-91.
27. Modi S, Elias AD, LoRusso P, et al. Results from a phase Ib study of trastuzumab emtansine (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab [abstract no. 528]. J Clin Oncol. 2012;30(15 Suppl 1).
28. Martin M, Garcia-Saenz JA, Dewar JA, et al. Interim results from a phase 1b/2a study of trastuzumab emtansine and docetaxel, with and without pertuzumab, in patients with HER2-positive locally advanced or metastatic breast cancer [abstract no. P5-18-05]. Cancer Res. 2012;72(24 Suppl 3):467s.
29. LoRusso P, Krop IE, Burris III HA, et al. Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 for patients with metastatic breast cancer who had progressed on prior HER2-directed therapy [abstract no. 1016]. J Clin Oncol. 2010;28(15 Suppl 1).
30. Perez EA, Hurvitz S, Amler LC, et al. Exploratory analysis of the relationship between HER2 expression (by QRT-PCR) and efficacy with first-line trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (HT) in a randomized phase 2 study of patients (pts) with HER2-positive MBC [abstract no. 226P]. Ann Oncol. 2012;23(Suppl 9):ix89.
31. Mahapatra K, Darbonne W, Bumbaca D, et al. T-DM1-induced thrombocytopenia results from impaired platelet production in a HER2-independent manner [abstract no. A135]. Mol Cancer Ther. 2011;10(11 Suppl 1).
32. Thon JN, Devine MT, Jurak Begonja A, et al. High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1): mediated inhibition of platelet production. Blood. 2012;120(10):1975-84.
33. Uppal H, Mahapatra K, Lewin-Koh SC, et al. Differential expression of microRNAs induced by trastuzumab emtansine (T-DM1) during megakaryocytopoiesis [abstract no. 645]. J Clin Oncol. 2013;31(15 Suppl 1).
34. Gupta M, LoRusso PM, Wang B, et al. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol. 2012;52(5):691-703.
35. Lu D, Joshi A, Wang B, et al. An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. Clin Pharmacokinet. 2013;52(8):657-72.
36. Lu D, Girish S, Gao Y, et al. Population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of various covariates [abstract no. P5-18-24]. Cancer Res. 2012;72(24 Suppl 3):475s.
37. Wang B, Jin J, Wada R, et al. Pharmacokinetics and exposure-efficacy relationship of trastuzumab emtansine in EMILIA, a phase 3 study of trastuzumab emtansine vs capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer [abstract no. P5-18-11]. Cancer Res. 2012;72(24 Suppl 3):469s.
38. Girish S, Gupta M, Wang B, et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol. 2012;69(5):1229-40.
39. Wang B, Jin J, Wada R, et al. Exposure-efficacy relationship of trastuzumab emtansine (T-DM1) in EMILIA, a phase III study of T-DM1 versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) [abstract no. 644]. J Clin Oncol. 2013;31(15 Suppl 1):644.
40. Wong S, Bumbaca D, Yue Q, et al. Nonclinical disposition, metabolism, and in vitro drug-drug interaction assessment of DM1, a component of trastuzumab emtansine (T-DM1) [abstract no. A136]. Mol Cancer Ther. 2011;10(11 Suppl 1).
41. Igawa Y, Matsubara M, Matsunaga K, et al. Pharmacokinetic (PK) and pharmacodynamic (PD) analysis of trastuzumab emtansine (T-DM1) in Japanese patients with advanced or recurrent HER2-positive breast cancer (JO22591): comparison with western patients [abstract no. PII-40]. Clin Pharmacol Ther. 2012;91(Suppl 1):S65-6.
42. Lu D, Burris HA III, Wang B, et al. Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer. Curr Drug Metab. 2012;13(7):911-22.
43. Baselga J, Verma S, Ro J, et al. Relationship between tumour biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC). [abstract no. LB-63]. Cancer Res. 2013;73(8 Suppl 1).
44. Yardley DA, Krop IE, LoRusso P, et al. Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): results from an expanded access study [abstract no. 166]. J Clin Oncol. 2013;31(26 Suppl).
45. Cardoso F, Harbeck N, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii11-9.
46. National Comprehensive Cancer Network. Breast cancer (version 1.2014). 2014. http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf. Accessed 4 Mar 2014.
47. Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012;21(3):242-52.
48. Tokuda Y, Suzuki Y, Saito Y, et al. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review. Breast Cancer. 2009;16(4):295-300.
49. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 2002;62(1):209-43.
50. Abramson VG, Mayer IA. Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer. Ther Adv Med Oncol. 2012;4(3):139-47.
51. Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol. 2013;76(2):248-62.
52. Brana I, Tabernero J. Cardiotoxicity. Ann Oncol. 2010;21(Suppl 7):vii173-9.
53. Ballantyne A, Dhillon S. Trastuzumab emtansine: first global approval. Drugs. 2013;73(7):755-65.
54. Ellis PA, Barrios CH, Im Y, et al. MARIANNE: a phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first- line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC) [abstract no. TPS102]. J Clin Oncol. 2011;29(15 Suppl).
55. Wildiers H, Kim SB, Gonzalez-Martin A, et al. T-DM1 for HER2-positive metastatic breast cancer (MBC): primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice [abstract no. LBA 15]. Eur J Cancer. 2013;49(Suppl 3):S7-8.
56. Beeram M, Krop IE, Burris HA, et al. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer. 2012;118(23):5733-40.